Apollomics (APLM) Long-Term Investments (2022 - 2025)

Apollomics (APLM) posted quarterly Long-Term Investments of $51.3 million for Q4 2025, down 26.8% quarter-over-quarter from $70.1 million in Q4 2023.

Apollomics (APLM) Long-Term Investments (2022 - 2025) Analysis & Trends

Apollomics (APLM) has reported Long-Term Investments for 3 consecutive years, with $51.3 million the latest figure, recorded in Q4 2025.

In Q4 2025, Long-Term Investments changed N/A year-over-year to $51.3 million; the TTM figure through Dec 2025 stood at $51.3 million (changed N/A YoY), while the FY2025 annual figure was $51.3 million, up 988.1% from the prior year.
Long-Term Investments fell to $51.3 million in Q4 2025 per APLM's latest filing, from $70.1 million in the prior quarter.
Across five years, Long-Term Investments topped out at $70.6 million in Q4 2022 and bottomed at $51.3 million in Q4 2025.
Historically, Long-Term Investments has averaged $64.0 million across 3 years, with a median of $70.1 million in 2023.
On a YoY basis, Long-Term Investments climbed as much as 0.65% in 2023 and fell as far as 0.65% in 2023.
Apollomics' Long-Term Investments stood at $70.6 million in 2022, then declined by 0.65% to $70.1 million in 2023, then decreased by 26.8% to $51.3 million in 2025.
Business Quant data shows APLM's Long-Term Investments at $51.3 million in Q4 2025, $70.1 million in Q4 2023, and $70.6 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	5.79 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	9.83 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	1.77 Bn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	22.17 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	372.10 Mn
10	Apollomics	35.18 Mn	31.90 Mn	-	51.32 Mn

Download Data